75 Recruiting Studies Using Palbociclib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Palbociclib
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
📍 Research Site — Tucson, Arizona
Locally Advanced (Inoperable) or Metastatic Breast Cancer
View Study & Checklist ➔To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
📍 Massachusetts General Hospital. — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
📍 University of Alabama at Birmingham/Children's of Alabama — Birmingham, Alabama
Ewing Sarcoma
View Study & Checklist ➔Study of INCB123667 in Subjects With Advanced Solid Tumors
📍 City of Hope Medical Center — Duarte, California
Solid Tumors
View Study & Checklist ➔Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Dedifferentiated Liposarcoma
View Study & Checklist ➔Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
📍 Pfizer New York — New York, New York
Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
📍 Orange Coast Memorial Medical Center — Fountain Valley, California
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
View Study & Checklist ➔Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
📍 Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital — Washington D.C., District of Columbia
Metastatic Breast Cancer
View Study & Checklist ➔DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
📍 University of Arizona Cancer Center — Tucson, Arizona
Breast Cancer
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
📍 Dothan Hematology and Oncology — Dothan, Alabama
Breast Cancer
View Study & Checklist ➔Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Well-differentiated/Dedifferentiated Liposarcoma
View Study & Checklist ➔Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
📍 City of Hope Corona — Corona, California
Metastatic Breast Carcinoma
View Study & Checklist ➔Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
📍 Stamford Hospital — Stamford, Connecticut
Breast Cancer
View Study & Checklist ➔Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
📍 Unversity of Nebraska Medical Center — Omaha, Nebraska
Breast Cancer
View Study & Checklist ➔Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
📍 City of Hope National Medical Center — Duarte, California
Mantle Cell Lymphoma
View Study & Checklist ➔Palbociclib After CDK and Endocrine Therapy (PACE)
📍 University of Miami — Miami, Florida
Metastatic Breast Cancer
View Study & Checklist ➔Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
📍 UCSF — San Francisco, California
HER-2 Positive Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
📍 UCSF Helen Diller Family CCC — San Francisco, California
Ovarian Cancer
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
📍 Arizona Oncology Associates Professional Corporation — Tucson, Arizona
Advanced Solid Tumors
View Study & Checklist ➔Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
📍 BRCR Global — Plantation, Florida
Breast Cancer
View Study & Checklist ➔A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
📍 Research Site — Mobile, Alabama
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
📍 Levine Cancer Institute — Charlotte, North Carolina
Female Breast Carcinoma
View Study & Checklist ➔Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
📍 Research Site — Phoenix, Arizona
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
📍 Georgetown University Medical Center ( Site 1002) — Washington D.C., District of Columbia
Renal Cell Carcinoma
View Study & Checklist ➔Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
📍 QEII Health Sciences Centre — Halifax, Nova Scotia
Prostate Cancer
View Study & Checklist ➔Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔PALbociclib CoLlaborative Adjuvant Study
📍 University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
📍 Beverly Hills Cancer Center — Beverly Hills, California
Breast Cancer
View Study & Checklist ➔Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
📍 Washington University School of Medicine — St Louis, Missouri
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
📍 University of Colorado — Aurora, Colorado
Breast Cancer
View Study & Checklist ➔Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
📍 Mount Sinai Beth Israel Comprehensive Cancer Center West — New York, New York
Breast Neoplasms
View Study & Checklist ➔A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
📍 Florida Cancer Specialists South - SCRI - PPDS — Sarasota, Florida
Receptors, Estrogen
View Study & Checklist ➔Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
📍 Memorial Sloan Kettering Cancer Center — Basking Ridge, New Jersey
Metastatic Breast Cancer (MBC)
View Study & Checklist ➔Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
📍 The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Exocrine Pancreas Carcinoma
View Study & Checklist ➔Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
📍 UCSF Medical Center at Mission Bay — San Francisco, California
Breast Cancer
View Study & Checklist ➔Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Lymphoblastic Leukemia
View Study & Checklist ➔Study of PF-07248144 in Advanced or Metastatic Solid Tumors
📍 HonorHealth — Scottsdale, Arizona
Locally Advanced or Metastatic ER+ HER2- Breast Cancer
View Study & Checklist ➔Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
📍 M D Anderson Cancer Center — Houston, Texas
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
📍 The University of Arizona Cancer Center — Tucson, Arizona
PIK3CA Mutation
View Study & Checklist ➔A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Well Differentiated Liposarcoma
View Study & Checklist ➔The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
📍 Research Site — St Louis, Missouri
ER+ HER2- Advanced Breast Cancer
View Study & Checklist ➔Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
📍 Cross Cancer Institute — Edmonton, Alberta
Lymphoma, Non-Hodgkin
View Study & Checklist ➔First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
📍 Ellison Clinic at Saint John's — Los Angeles, California
Breast Cancer
View Study & Checklist ➔A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
Breast Neoplasms
View Study & Checklist ➔A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
📍 Brigham and Women's Hospital — Boston, Massachusetts
Metastatic Renal Cell Carcinoma
View Study & Checklist ➔A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
Advanced Solid Tumor
View Study & Checklist ➔Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Tumor, Solid
View Study & Checklist ➔Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
📍 Sanford Worthington Medical Center — Worthington, Minnesota
HPV-unrelated Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
📍 Alabama Oncology Princeton — Birmingham, Alabama
HR+/HER2- Breast Cancer
View Study & Checklist ➔Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
📍 Georgetown University — Washington D.C., District of Columbia
Breast Cancer
View Study & Checklist ➔Combined Immunotherapies in Metastatic ER+ Breast Cancer
📍 Weill Cornell Medicine — New York, New York
Breast Cancer
View Study & Checklist ➔Palbociclib and Pembrolizumab In Central Nervous System Metastases
📍 Massachusetts General Hospital — Boston, Massachusetts
Metastatic Malignant Neoplasm to Brain
View Study & Checklist ➔Study of AVZO-021 in Patients With Advanced Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
📍 City of Hope — Duarte, California
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
View Study & Checklist ➔Palbociclib and Pembrolizumab in Sarcoma
📍 University of Iowa Hospitals & Clinics — Iowa City, Iowa
Sarcoma
View Study & Checklist ➔A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
📍 Northwestern Memorial Hospital — Chicago, Illinois
HR+/HER2-negative Breast Cancer
View Study & Checklist ➔Pilot Trial for Treatment of Recurrent Glioblastoma
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Glioblastoma
View Study & Checklist ➔Tazemetostat and Palbociclib With CPX-351for R/R AML
📍 Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
📍 City of Hope — Duarte, California
Metastatic Breast Cancer
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
📍 Southern Cancer Center — Daphne, Alabama
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
View Study & Checklist ➔TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
📍 University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
Lymphoma, Non-Hodgkin
View Study & Checklist ➔Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Malignant Female Reproductive System Neoplasm
View Study & Checklist ➔SNV4818 in Participants With Advanced Solid Tumors
📍 The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
Advanced Solid Tumors
View Study & Checklist ➔Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
📍 Research Site — Gilbert, Arizona
Advanced Breast Cancer
View Study & Checklist ➔